Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cerenis brings in €50mm via its Series C round

Executive Summary

Cerenis Therapeutics SA (cardiovascular and metabolic conditions) has raised €40mm ($51.9mm) through the first closing of its Series C venture round. The Fund for Strategic Investment provided €20mm and the remainder came from current shareholders Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed, and Daiwa Corporate Investment. The money will be used to continue developing Phase II CER001 for cardiovascular disease and to work on other HDL drug candidates. The same day it announced the Series C round, Cerenis received €10.7mm from the French government.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies